Update Research in Psoriasis
DOI:
https://doi.org/10.53469/jcmp.2024.06(07).18Keywords:
NAAbstract
Psoriasis is now considered a chronic inflammatory and proliferative skin disease mediated by lymphocytes. In European countries, the prevalence of psoriasis is 1%~3%, so the study of psoriasis is very important. Through research into immune pathogenesis and advances in genetic engineering techniques, it has progressively developed a wide range of biological agents with promising results in clinical trials or treatments. This paper discusses the typical clinical manifestations, genetic research and treatment of psoriasis.
References
Christopher EM Griffiths, Jonathan NWN Barker. Pathogenesis and clinical features of psoriasis[J]. The Lancet,2007,370(9583).
SHI Yu-ling. Interpretation of guideline for the diagnosis and treatment of psoriasis in China (2018 edition) [J]. JOURNAL OF TONGJI UNIVERSITY (MEDICAL SCIENCE), 2019, 40(03): 265-267. DOI:10.16118/j.1008-0392.2019.03.001.
DAI Dan, CHEN Yanhua, HE Chunyan, WANG Shuo, SONG Ping. Targeted Lipidomics Reveals Lipids Modulation of Kaixuan Bushen Method on Psoriasis Vulgaris. [J/OL]. Chinese Journal of Experimental Traditional Medical Formulae: 1-9[2022-10-19]. DOI:10.13422/j.cnki.syfjx.20220749.
Kudsi Mayssoun, Alzabibi Mhd Amin, Shibani Mosa. Two cases of Erythrodermic psoriasis treated with Golimumab[J]. Annals of Medicine and Surgery,2022,78.
Misha Rosenbach, Sylvia Hsu, Neil J. Korman, Mark G. Lebwohl, Melodie Young, Bruce F. Bebo, Abby S. Van Voorhees. Treatment of erythrodermic psoriasis: From the medical board of the National Psoriasis Foundation[J]. Journal of the American Academy of Dermatology,2009,62(4).
GU Yuanxia, WANG Yiyi, XIAO Yue, LI Wei. Applications of Genomics in Psoriatic Arthritis [J/OL] The Chinese Journal of Dermatovenereology.: 1-7[2022-10-20]. DOI:10.13735/j.cjdv.1001-7089. 202207144.
Lønnberg A S, Skov L, Skytthe A, Kyvik K O, Pedersen O B, Thomsen S F. Heritability of psoriasis in a large twin sample. [J]. The British journal of dermatology,2013,169(2).
Allen Michael Hugh, Ameen Hahreen, Veal Colin, Evans Julie, Ramrakha-Jones V S, Marsland A M, Burden A David, Griffiths C E M, Trembath Richard C, Barker Jonathan N W N. The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis. [J]. The Journal of investigative dermatology,2005,124(1).
Kotaro Ogawa, Yukinori Okada. The current landscape of psoriasis genetics in 2020[J]. Journal of Dermatological Science,2020,99(1).
Rahman Mahfoozur, Alam Kainat, Ahmad Mohammad Zaki, Gupta Gaurav, Afzal Muhammad, Akhter Sohail, Kazmi Imran,Jyoti, Ahmad Farhan Jalees, Anwar Firoz. Classical to current approach for treatment of psoriasis: a review. [J]. Endocrine, metabolic & immune disorders drug targets,2012,12(3).
WANG Ziyue, PENG Yuting, CHEN Aijun, WANG Pin. Molecular and Cellular Mechanisms of Phototherapy for Psoriasis[J]. Chin J Derm Venereol, 2022,36(10): 1113 – 1117.DOI:10.13735/j.cjdv.1001-7089.202204097.
Alan Menter, Kelly M. Cordoro, Dawn M.R. et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients[J]. Journal of the American Academy of Dermatology,2020,82(1).
WANG Xiaojin, ZHANG Jianying, ZHANG Shouliang, WANG Haijun. Mechanism of Traditional Chinese Medicine in the Prevention and Treatment of Psoriasis: A Review[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2022,28(21):243-253. DOI:10.13422/j.cnki.syfjx.20221413.
Tamilselvi Elango, Haripriya Dayalan, Swapna Subramanian, Pushpa Gnanaraj, Hemamalini Malligarjunan. Serum interleukin‐6 levels in response to methotrexate treatment in psoriatic patients[J]. Clinica Chimica Acta,2012,413(19-20).
Howard Scott C, McCormick John, Pui Ching-Hon, Buddington Randall K, Harvey R Donald. Preventing and Managing Toxicities of High-Dose Methotrexate. [J]. The oncologist,2016,21(12).
Lee Chai Sue, Li Kai. A review of acitretin for the treatment of psoriasis. [J]. Expert opinion on drug safety,2009,8(6).
Hari Gangadhar, Kishore Anoop, Karkala Sreedhara Ranganath Pai. Treatments for psoriasis: A journey from classical to advanced therapies. How far have we reached? [J]. European Journal of Pharmacology, 2022,929.
Lu Cuicui, Lu Shuzhen, ZHOU Chuanbo. Comparison on Efficacy of Infliximab Combined With Mercaptopurine and Monotherapy for Inflammatory Bowel. [J]. Chin J Gastroenterol.2018,23(07):416-422.
Qin Yue-ning. Observation of Effects and Adverse Reactions of Infliximab in Treatment of Moderate to Severe Psoriasis[J]. Chinese Community Doctors, 2022,38(01):30-32.
Lockwood Stephen J, Prens Lisette M, Kimball Alexa B. Adverse Reactions to Biologics in Psoriasis. [J]. Current problems in dermatology,2018,53.
Shawky Ahmed M., Almalki Faisal A., Abdalla Ashraf N., Abdelazeem Ahmed H., Gouda Ahmed M.. A Comprehensive Overview of Globally Approved JAK Inhibitors[J]. Pharmaceutics,2022,14(5).
Calautti E, Avalle L, Poli V. Psoriasis: a STAT3--centric view[J]. Int J Mol Sci,2018,19(1): 171.
Pablo Olivera, Juan Lasa, Stefanos Bonovas, Silvio Danese, Laurent Peyrin-Biroulet. Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis[J]. Gastroenterology, 2020, 158(6).
Susan H. Smith, Channa Jayawickreme, David J. et al. Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans[J]. Journal of Investigative Dermatology, 2017,137(10).
SUN Yue, SHI Yu, WEI Bo. et al. Research progress on small molecule drugs for treatment of psoriasis [J]. Drugs & Clinic,2014,29(11):1318-1325.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Jiawei Wu, Xiaoning Yan
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
